Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exploring Kawasaki Disease

Mary Beth Son, MD  |  Issue: April 2014  |  April 2, 2014

Fever is the cardinal feature of KD and tends to be of abrupt onset. The fevers are typically high, above 39°C (102.2°F), and don’t necessarily remit with antipyretics. According to the classic case definition, fever should be present for longer than four days, although the presence of at least four stigmata of KD on Day 4 of fever permits the diagnosis of KD. Those children who have fewer than four criteria but evidence of coronary artery involvement on echocardiography also meet the case definition. In Japan, children who have four or fewer days of fever but whose illness has been shortened by the administration of IVIG also meet diagnostic criteria.

There is no specific rash for KD, although it is commonly a diffuse, maculopapular rash that begins on the trunk. Desquamation in the perineal area is also common in the first week of illness. Morbilliform rashes, erythroderma and erythema multiforme have all been described in patients with KD. Bullous or vesicular rashes are not typical. Conjunctival injection without discharge that spares the limbus (the transitional zone between the cornea and the conjunctiva) is seen in greater than 90% of children with KD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are several findings in the oropharynx, including a strawberry tongue, a diffusely red oropharynx without ulcers or exudate, and erythematous, cracked lips.

There are two phases to the extremity changes seen in KD: With fever, children have firm swelling of the hands and feet with erythema of the palms and soles. Two to three weeks following fever onset and in the subacute period, periungual peeling, first in the hands and then the feet, appears.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The least commonly seen of the criteria is unilateral cervical chain lymph node swelling, less than 1.5 cm in diameter, which usually appears as a group of matted nodes on imaging.

The classic case criteria were developed as a means to perform surveillance of the disease in Japan, and to distinguish KD from acute rheumatic fever and Stevens-Johnson syndrome. It has become clear to clinicians that not all children with KD meet the classic clinical criteria, but some are at higher risk for coronary artery abnormalities (CAA).11 An algorithm utilizing laboratory and echocardiographic data has been developed by the AHA to assist clinicians in diagnosing children with fever of five days or longer and two or three features of KD (Figure 1).2 A retrospective study of patients with KD and coronary artery aneurysms showed that the algorithm correctly identified 97% of children with fewer than four stigmata for treatment with IVIG.12

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:ACR/ARHP Annual Meetingimmune intravenous globulininfliximabJuvenile idiopathic arthritisKawasaki diseasepatient carerheumatologist

Related Articles
    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    The Mystery of IVIg

    March 8, 2012

    Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

    Dr. Kawasaki

    Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

    June 18, 2020

    Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

    Thinking Big, Thinking Small

    June 17, 2019

    I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences